<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01436123</url>
  </required_header>
  <id_info>
    <org_study_id>NANOM PCI</org_study_id>
    <nct_id>NCT01436123</nct_id>
  </id_info>
  <brief_title>Plasmonic Photothermal and Stem Cell Therapy of Atherosclerosis Versus Stenting</brief_title>
  <acronym>NANOM PCI</acronym>
  <official_title>Plasmonic Photothermal and Stem Cell Therapy of Atherosclerosis With The Use of Gold Nanoparticles With Iron Oxide-Silica Shells Versus Stenting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ural State Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ural Institute of Cardiology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>De Haar Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ural Federal University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ural State Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intensive therapy with rosuvastatin 40 mg and ApoA-I Milano reduces the total atheroma volume&#xD;
      (TAV) up to 6.38 or 14.1 mm3 respectively. Our previous bench studies PLASMONICS and NANOM&#xD;
      First-in-Man trial documented TAV reduction up to unprecedented 79.4 and 60.3 mm3&#xD;
      respectively with high level of safety and feasibility.&#xD;
&#xD;
      The completed randomized two arm (1:1) study (NANOM-PCI) with parallel assignment (n=62)&#xD;
      assessed (NCT01436123) the safety and feasibility of the delivery technique for nanoparticles&#xD;
      (NP) using micro-injection catheter (with intravascular intramural injection of allogeneous&#xD;
      stem cells carrying NP after MSCT-, IVUS- and OCT-guided mapping of the vessel), and&#xD;
      plasmonic photothermal therapy of atherosclerosis combined with stenting (Nano group, n=32)&#xD;
      versus stenting with Xience V cage (Stenting group, n=30). The primary outcome was TAV at 12&#xD;
      months.&#xD;
&#xD;
      The mean reduction of TAV at 12 months in Nano group was -84.1 mm3 (95% CI: SD 28.3; min&#xD;
      -52.4 mm3, max -99.1 mm3; p&lt;0.05) versus +12.4 mm3 in case of stenting (p&lt;0.05 between&#xD;
      groups). 42/62 patients (68%) in Nano group passed the Glagov threshold of a 40% plaque&#xD;
      burden with mean plaque burden (PB) 36.2% (95% CI: SD 9.3%, min 30.9%, max 44.5%). The&#xD;
      increase of the minimal lumen diameter was 61.2 and 63.3% at 12 month follow up in groups&#xD;
      respectively. The serial assessment of VH-IVUS showed a significant decrease at 12 months in&#xD;
      the dense calcium area, fibrous and fibro-fatty tissue with fulminant necrosis due to&#xD;
      thermolysis in Nano-group, whereas an increase of fibrous and fibro-fatty components in&#xD;
      stenting arm. We have documented 2 vs 3 cases of the definite thrombosis and 3 vs 5 cases of&#xD;
      target lesion revascularization in groups respectively. The analysis of the event-free&#xD;
      survival of the ongoing clinical follow-up shows the significantly lower risk of&#xD;
      cardiovascular death in Nano group if compare with conventional stenting (93.4% vs 86.7%;&#xD;
      p&lt;0.05).&#xD;
&#xD;
      Plasmonic resonance-mediated therapy using noble-metal NP associated with significant&#xD;
      regression of coronary atherosclerosis. Tested delivery approach has acceptable safety and&#xD;
      efficacy for atheroregression below a 40% PB.&#xD;
&#xD;
      The investigators hypothesize that multistep approach with the use of stent in acute care&#xD;
      unit, and then subsequent transcatheter micro-injection with nanoparticles can resolve&#xD;
      atherosclerosis, stop and regress atherogenesis, remodulate or even rejuvenate arteries. Stem&#xD;
      cells in patch can be good carriers for nanoparticles as well as high-effective metabolic&#xD;
      vectors (paracrine-like regulation of alive cells and via bioactive products of cell lysis&#xD;
      after detonation of nanoparticles) for the treatment of plaque on site. Gold nanoparticles&#xD;
      with silica-iron oxide shells promise high-energy plasmonic photothermic burning or melting&#xD;
      effect under the near-infrared laser irradiation onto the lesion. Thus the investigators&#xD;
      expect complex two-side effect on the plaque with protected lumen and adventitia.&#xD;
&#xD;
      Novel discoveries in atherogenesis, and development of nanobiotechnologies with potentials&#xD;
      for the management of atherosclerosis leads us to the quest of new approaches. The&#xD;
      investigators still cannot really effectively treat atherosclerosis.&#xD;
&#xD;
      The investigators management is more symptomatic, and lipid-pool or inflammation-oriented!&#xD;
      The investigators cannot manage non-organic part (mineral deposits, calcified necrotic core,&#xD;
      partially collagen and fibrotic tissue) and total plaque volume Surgery and invasive&#xD;
      procedures is just focused on blood flow restoration (just manipulate the form of plaque) +&#xD;
      concerns of clinical and technical restrictions (incl. alien body - stent) + risk of&#xD;
      restenosis or subacute 'fatal' in-stent atherothrombosis + graft survival/ occlusion +&#xD;
      surgery-related complications High rate of short- and long-term complications and&#xD;
      readmissions. Regression of atherosclerosis in fact is still a dream. The investigators offer&#xD;
      an alternative to stenting and may be cardiac artery bypass surgery (CABG). Our approach can&#xD;
      really allow to rejuvenate arteries, Plasmonic photothermal therapy (PPTT) can burn plaque,&#xD;
      but stem cells and bioengineered structures promise restoration of the vessel wall.&#xD;
&#xD;
      Our personal previous data showed that PPTT can 1.6-fold reduce a volume of plaque with most&#xD;
      optimal long-term result in subsets with the use of SPCs as a delivery approach. The most&#xD;
      optimal delivery systems of NPs into the plaque are the on-artery bioengineered patch and&#xD;
      ferro-magnetic approach.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nanoparticles (NPs) are quite safe for an organism but entire kinetics is mostly unknown. The&#xD;
      most dangerous approach with lowest level of efficacy and safety is a delivery of NPs with&#xD;
      microbubbles. SP+ and mesenchymal SPCs have the similar efficacy as a local delivery system&#xD;
      with a lot of beneficial properties such as anti-inflammative, anti-apoptotic, and&#xD;
      multi-metabolic effects leading to the plaque degradation and artery rejuvenation. Thus,&#xD;
      nanoburning is very challenging technique to demolish and reverse the plaque especially in&#xD;
      combination with stem cell technologies promising functional restoration of the vessel wall&#xD;
      and can be an alternative to stenting.&#xD;
&#xD;
      Altering general strategy the investigators generally offer:&#xD;
&#xD;
        1. The investigators don't need a therapy only with harvested stem cells (not so effective,&#xD;
           but more provocative); the investigators have to manage host resident stem cells on site&#xD;
           [local in-artery infusion] with growth factors, cytokines [or systemic potentiation, but&#xD;
           risk of side effects and adverse events is high].&#xD;
&#xD;
        2. Regular intravenous systemic therapy with modified BM (bone marrow), circulating&#xD;
           progenitor, and iPS (induced pluripotent) stem cells might be beneficial for prevention&#xD;
           of diseases, and rejuvenation of tissues and organs - but the system as whole will be&#xD;
           compromised [the investigators can store stem cells of each individual to use for cell&#xD;
           therapy or bioengineering].&#xD;
&#xD;
        3. The best way - development of bioengineered constructions through life to transplant a&#xD;
           bioartificial organ on request.&#xD;
&#xD;
        4. Multi-step invasive treatment of atherosclerosis - (1) biodegradable stenting in ACU&#xD;
           (acute care unit), or preventively, with no restenosis and no acute atherothrombosis&#xD;
           risk profile, (2) regular systemic or local stem cell therapy, or with cytokines, (3)&#xD;
           on-artery MSCs (mesenchymal stem cells)-related bioengineered patch with silica-gold&#xD;
           iron-bearing NPs [SCs (stem cells) as carriers for NPs with transduction in hands of&#xD;
           magnetic fields for local elimination of plaque, and subsequent rejuvenation of artery&#xD;
           wall.&#xD;
&#xD;
      Our new approach, challenging modern therapy of atherosclerosis include:&#xD;
&#xD;
        1. BIODEGRADABLE STENTS - for 6-24 months period under the soft short-term antithrombotic&#xD;
           therapy (resolving concerns with stenosis/ lumen + steered remodeling); no hemorrhages,&#xD;
           no alien metal body, no concerns with further CABG, minimal inflammation&#xD;
&#xD;
        2. INTRAVENOUS NON-SPECIFIC SYSTEMIC STEM CELL THERAPY - before and after stenting - launch&#xD;
           repair effects in vessel + beneficial effects for ischemic or injured tissues&#xD;
&#xD;
        3. ON-ARTERY BIOENGINEERED PATCH transplantation with NPs or MICRO-INFUSION of stem cells&#xD;
           bearing NP - grown with MSCs and NPs (bovine pericardium scaffold); 3-6 weeks to grow a&#xD;
           thin structure (recover cells before or during stenting), multi-effects due to migration&#xD;
           of SCs + bioactive products of lysis&#xD;
&#xD;
        4. PLASMONIC PHOTOTHERMAL THERAPY - 'melting' and 'burning' effects - direct degradation +&#xD;
           bioactive products of stem cells' lysis + further migration of SCs from patch&#xD;
&#xD;
      Potential expected disadvantages of our approach: Necessity of the special precise delivery&#xD;
      technique. Lost function of artery - irreparable pro-fibrotic and pro-inflammative damage -&#xD;
      necessity of another clinical approach for restoration of tissue (may be with stem cells).&#xD;
      Threat of acute fatal atherothrombosis due to rupture of (vulnerable) plaque - verification&#xD;
      of the optimal antithrombotic therapy. Cannot treat non-organic part of plaque - necessity of&#xD;
      the special therapy for mineral deposits, calcified necrotic core, fibrotic sites - solution&#xD;
      using stem cells. Harm of potent detrimental adverse effects - vapor bubbling (boiling of&#xD;
      cytoplasm and ECM with subsequent lysis of cells, and provocation of pro-apoptotic cascades),&#xD;
      acoustic and shock waves due to plasma-generated laser-related detonation of nanoshells in&#xD;
      tissue - need regenerative therapy (type of SCs, conditions and way of transplantation;&#xD;
      Culturing? Sorting?). Erratic (unsteered) heating - surrounding tissue of the site of&#xD;
      interest can achieve a temperature until 38-39Â°. But at the site of burning final temperature&#xD;
      can be at about 50-180 C (cauterization/ searing/ melting effect) with consequent&#xD;
      pro-fibrotic effect - need regenerative therapy and clarification of energy options.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The study was terminated under the political pressure of the Federal Security Service of the&#xD;
    Russian Federation (FSB) and the Russian Society of Cardiology&#xD;
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total atheroma volume</measure>
    <time_frame>at month 12</time_frame>
    <description>Total plaque volume measured by intravascular ultrasound (IVUS), cubic mm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite end-point of any MACE (major acute cardiovascular events), all-cause death, any revascularization</measure>
    <time_frame>at month 12</time_frame>
    <description>Composite end-point of all-cause death, all MACE - major cardiovascular events, any revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composition of plaque</measure>
    <time_frame>at month 12</time_frame>
    <description>Analysis of IVUS(intravascular ultrasound)-related composition of plaque (calcified deposits, necrotic calcified core), fibro-lipid core and etc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major and minor bleeding</measure>
    <time_frame>at month 12</time_frame>
    <description>Clinical examination of major and minor bleeding under the antithrombotic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restenosis rate</measure>
    <time_frame>at month 12</time_frame>
    <description>Restenosis rate verified clinically + IVUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis rate</measure>
    <time_frame>at month 12</time_frame>
    <description>Stent thrombosis rate verified clinically, angiography, IVUS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary flow-mediated vasodilatation</measure>
    <time_frame>at month 12</time_frame>
    <description>Ultrasound-related examination of coronary flow-mediated vasodilatation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coronary intima-media thickness</measure>
    <time_frame>at month 12</time_frame>
    <description>Ultrasound-IVUS-related examination of coronary intima-media thickness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum diameter stenosis</measure>
    <time_frame>at month 12</time_frame>
    <description>IVUS-related assessment of minimum diameter stenosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum lumen diameter</measure>
    <time_frame>at month 12</time_frame>
    <description>IVUS-related assessment of minimum lumen diameter</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Stenting + Micro-infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Step 1 - implantation of everolimus-eluting stent with imaging by MSCT, IVUS and OCT; Step 2 - injection of stem cells containing gold nanoparticles with silica-iron oxide shells.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stenting</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Put in everolimus-eluting stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stenting and micro-infusion of NP</intervention_name>
    <description>Step 1 - IVUS, OCT-guided put in everolimus-eluting (drug-eluting-DES) stent + intravascular ultrasound (IVUS) mapping + harvesting stem cells with mesenchymal phenotype; Step 2 - culturing of stem cells in medium by gold nanoparticles with silica-iron oxide shells; Step 3 - micro-infusion of stem cells bearing NP into the lesion; Step 4 - detonation of nanoshells after migration of stem cells with NPs inside (until 7-10 days after transplantation). We expect 'melting' and 'burning' effects of PPTT, beneficial effects of bioactive products of stem cells lysis + benefits from further migration of stem cells from patch into the plaque</description>
    <arm_group_label>Stenting + Micro-infusion</arm_group_label>
    <other_name>Plasmonic Photothermal Therapy (PPTT)</other_name>
    <other_name>Stem cell therapy</other_name>
    <other_name>Bioengineering</other_name>
    <other_name>Stenting</other_name>
    <other_name>Xience V stent</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of everolimus-eluting stent</intervention_name>
    <description>Put stent in ischemia-related coronary artery by indications for PCI</description>
    <arm_group_label>Stenting</arm_group_label>
    <other_name>Stenting</other_name>
    <other_name>Xience V stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Multivessel coronary artery disease without indications for CABG&#xD;
&#xD;
          -  Stable angina with indications for preventive PCI&#xD;
&#xD;
          -  NSTEMI (primary PCI and late comers) &lt;=&gt; 12 hr&#xD;
&#xD;
          -  STEMI with kept EF&gt;50% (all comers)&#xD;
&#xD;
          -  Rescue PCI&#xD;
&#xD;
          -  Vessel size between 2.3-4.0 mm&#xD;
&#xD;
          -  NYHA II-III functional class of HF&#xD;
&#xD;
          -  De novo treatment = no history of PCI or CABG&#xD;
&#xD;
          -  Atherosclerosis of proximal left anterior descending artery &lt;50% stenosis&#xD;
&#xD;
          -  Treated hypertension&#xD;
&#xD;
          -  Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of MI&#xD;
&#xD;
          -  History of CABG or PCI&#xD;
&#xD;
          -  Indications for CABG&#xD;
&#xD;
          -  Contraindications for CABG, PCI&#xD;
&#xD;
          -  History of unstable angina, coronary artery syndrome&#xD;
&#xD;
          -  History of arrhythmias&#xD;
&#xD;
          -  History of stroke&#xD;
&#xD;
          -  NYHA I, IV functional class of HF&#xD;
&#xD;
          -  Diabetes (fasting glucose &gt; 7.0 mM/L)&#xD;
&#xD;
          -  Untreated hypertension&#xD;
&#xD;
          -  Asthma&#xD;
&#xD;
          -  Participation to any drug-investigations during previous 60 days&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Intolerance to any limus drugs, aspirin, clopidogrel, aspirin, metals and polymers of&#xD;
             stent and nanoparticles&#xD;
&#xD;
          -  Need for chronic treatment with anti-vitamin K drugs&#xD;
&#xD;
          -  Impossibility of clinical follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Kharlamov, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ural Institute of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Gabinsky, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Ural Institute of Cardiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olga Kovtun, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Ural State Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>De Haar Research Foundation</name>
      <address>
        <city>Rotterdam</city>
        <state>South Holland</state>
        <zip>3071PR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ural Center of Modern Nanotechnologies, Institute of Natural Sciences, Ural Federal University</name>
      <address>
        <city>Yekaterinburg</city>
        <state>Sverdlovsk oblast</state>
        <zip>620000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ural Institute of Cardiology</name>
      <address>
        <city>Yekaterinburg</city>
        <state>Sverdlovsk oblast</state>
        <zip>620144</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Russian Federation</country>
  </location_countries>
  <link>
    <url>http://www.cardio-burg.ru</url>
    <description>Ural Institute of Cardiology</description>
  </link>
  <link>
    <url>http://www.usma.ru</url>
    <description>Ural State Medical Academy</description>
  </link>
  <link>
    <url>http://nanocenter.urfu.ru</url>
    <description>Nanocenter of the Ural Federal University</description>
  </link>
  <reference>
    <citation>Kharlamov AN. Plasmonic photothermal therapy for atheroregression below Glagov threshold. Future Cardiol. 2013 May;9(3):405-25. doi: 10.2217/fca.13.16. Review.</citation>
    <PMID>23668744</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>September 14, 2011</study_first_submitted>
  <study_first_submitted_qc>September 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <last_update_submitted>May 17, 2015</last_update_submitted>
  <last_update_submitted_qc>May 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ural State Medical University</investigator_affiliation>
    <investigator_full_name>Alexander Kharlamov</investigator_full_name>
    <investigator_title>Research manager</investigator_title>
  </responsible_party>
  <keyword>Plasmonic Photothermal Therapy</keyword>
  <keyword>Nanoparticles</keyword>
  <keyword>Stem cells</keyword>
  <keyword>Atherosclerosis</keyword>
  <keyword>Bioengineering</keyword>
  <keyword>Biodegradable stenting</keyword>
  <keyword>Repair disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

